Notably, the administration of PGE2 or EP1 antagonists can alleviate renal dysfunction in the hypertensive SHRSP model, which leads to the development of renal fibrosis with progressing hypertension [57]. This evidence concerns the gene PTGER1 and hypertensive disorder.